To target or not to target APRIL in systemic lupus erythematosus: that is the question!

Among the cytokines that regulate B cell homeostasis are the TNF-like ligands BLyS (B lymphocyte stimulator, also called BAFF for B cell activation factor) and APRIL (a proliferation inducing ligand). BLyS and APRIL share two receptors, i.e.

BCMA (B-cell maturation antigen) and TACI (transmembrane activator and CAML interactor). Therapeutic approaches using biologics are limited for treatment of lupus patients.

One previously approved drug is belimumab that antagonizes the B cell stimulator BLyS. Another biologic inhibiting BLyS and APRIL -atacicept- was terminated for serious adverse events raising the question whether APRIL should be neutralized in auto-immunes diseases.

Author: Jacques MorelMichael Hahne
Credits/Source: Arthritis Research &Therapy 2013, 15:107

Published on: 2013-02-25

Copyright by the authors listed above - made available via BioMedCentral (Open Access). Please make sure to read our disclaimer prior to contacting 7thSpace Interactive. To contact our editors, visit our online helpdesk. If you wish submit your own press release, click here.


Custom Search


© 2015 7thSpace Interactive
All Rights Reserved - About | Disclaimer | Helpdesk